Results 11 to 20 of about 80,018 (239)

Oxidative stress in the pathogenesis of systemic scleroderma: An overview [PDF]

, 2018
Systemic sclerosis (SSc) is a rare disorder of the connective tissue characterized by fibrosis of the skin, skeletal muscles and visceral organs. Additional manifestations include activation of the immune system and vascular injury. SSc causes disability
Gambardella, Lucrezia, Giovannetti, Antonello, Malorni, Walter, Pietraforte, Donatella, Straface, Elisabetta, Vona, Rosa   +5 more
core   +1 more source

Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations

BMJ Open, 2020
Introduction Transparent collaborations between patient organisations (POs) and clinical research sponsors (CRS) can identify and address the unmet needs of patients and caregivers.
Ilaria Galetti, Maureen Sauve, Catarina Leite, Joep Welling, Martina Gahlemann, Annelise Roennow, Robert J Riggs, Ann Tyrrell Kennedy, Edith Brown, Alex Gonzalez, Alexandra Paula Portales Guiraud, François Houÿez, Rob Camp, Annie Gilbert, Lizette Moros, Jose Luis Luna Flores, Friedrich Schmidt, Wiebke Sauter, Henrik Finnern   +18 more
doaj   +1 more source

Advanced Autoantibody Testing in Systemic Sclerosis

Diagnostics, 2023
Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication.
Kholoud Almaabdi, Zareen Ahmad, Sindhu R. Johnson   +2 more
doaj   +1 more source

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis

Frontiers in Immunology, 2018
Systemic sclerosis (SSc) is a poorly understood heterogeneous condition with progressive multi-organ fibrosis. Recent genetic and genomic evidence suggest a pathogenic role for dysregulated innate immunity and toll-like receptor (TLR) activity in SSc ...
Swati Bhattacharyya, Wenxia Wang, Zenshiro Tamaki, Bo Shi, Anjana Yeldandi, Yasuhiro Tsukimi, Masashi Yamasaki, John Varga   +7 more
doaj   +1 more source

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. [PDF]

, 2017
Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled
Boin, Francesco, Carns, Mary, Chung, Lorinda, Criswell, Lindsey A, Derk, Chris T, Domsic, Robyn T, Gladue, Heather, Goldberg, Avram, Gordon, Jessica K, Gourh, Pravitt, Hsu, Vivien, Jan, Reem, Kastner, Daniel L, Khanna, Dinesh, Mayes, Maureen D, Medsger, Thomas A, Morgan, Nadia D, Ramos, Paula S, Remmers, Elaine F, Saketkoo, Lesley A, Schiopu, Elena, Shah, Ami A, Shanmugam, Victoria K, Silver, Richard M, Steen, Virginia D, Trojanowski, Marcin A, Valenzuela, Antonia, Varga, John, Wigley, Fredrick M   +28 more
core   +1 more source

Localized scleroderma: clinical spectrum and therapeutic update [PDF]

Anais Brasileiros de Dermatologia, 2015
Scleroderma is a rare connective tissue disease that is manifested by cutaneous sclerosis and variable systemic involvement. Two categories of scleroderma are known: systemic sclerosis, characterized by cutaneous sclerosis ...
Mariana Figueiroa Careta, Ricardo Romiti
doaj   +2 more sources

A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. [PDF]

, 2012
OBJECTIVE: A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset.
Jimenez, Sergio A., Lee, MD, Jason B., Mendoza, MD, Fabian A., Nagle, Sarah J.   +3 more
core   +3 more sources

Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics

Pharmaceuticals, 2023
Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune diseases.
Michael Macklin, Sudeep Yadav, Reem Jan, Pankti Reid   +3 more
doaj   +1 more source

From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution

Dermatology Research and Practice, 2018
Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features. We evaluated the relationship between SSc and LoS in our case series of SSc patients. Methods.
Giuggioli Dilia, Colaci Michele, Cocchiara Emanuele, Spinella Amelia, Lumetti Federica, Ferri Clodoveo   +5 more
doaj   +1 more source

Adipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis

Arthritis Research & Therapy, 2018
Background A pivotal role for adipose tissue homeostasis in systemic sclerosis (SSc) skin fibrosis is increasingly recognized. The nuclear receptor PPAR-γ is the master regulator of adipogenesis.
Benjamin Korman, Roberta Goncalves Marangoni, Gabriel Lord, Jerrold Olefsky, Warren Tourtellotte, John Varga   +5 more
doaj   +1 more source